Indicated for: non-small cell lung cancer
Route of administration: oral
Substance: gefitinib (tyrosine kinase inhibitor)
ATC: L01EB01 (Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors)
Gefitinib is a medication used for the treatment of non-small cell lung cancer, particularly in patients with epidermal growth factor receptor (EGFR) mutations. It is a tyrosine kinase inhibitor.
This medication works by blocking signals that promote the growth and division of cancer cells. It is taken orally, usually once daily, as directed by a doctor.
Common side effects include diarrhea, skin rash, nausea, and fatigue. In rare cases, severe reactions such as interstitial lung disease may occur.
It is important to follow your doctor's instructions closely and report any side effects or unusual symptoms. Regular monitoring is necessary to assess treatment effectiveness.